A schedule for combined intravenous and oral dosing with mexiletine

A combined intravenous and oral dosage regime for mexiletine has been evaluated in volunteer subjects. Therapeutically effective plasma concentrations of the drug were achieved rapidly and maintained over a four-hour period. Side-effects were minimal and the scheme would be suitable for the anti-arrhythmic protection of patients being transported to hospital and for the treatment of patients receiving hospital or, even, domicilliary care.